Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Hepatic Portal System01:21

Hepatic Portal System

5.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.0K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

332
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
332
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.1K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

690
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
690
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Correction: Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Reviews in endocrine & metabolic disorders·2026
Same author

Global disparities in hepatocellular carcinoma outcomes: multicentre study.

The British journal of surgery·2026
Same author

MASLD prevalence, incidence and global aspects.

Diabetologia·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same author

Elimination in the age of retrenchment: what hepatitis reveals about the future of global health.

The Lancet. Global health·2026
Same author

Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Reviews in endocrine & metabolic disorders·2026
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Hepatitis C y otras enfermedades

C Wendy Spearman1, Geoffrey M Dusheiko2, Margaret Hellard3

  • 1Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Lancet (London, England)
|October 22, 2019
PubMed
Resumen
Este resumen es generado por máquina.

El virus de la hepatitis C (VHC) afecta a millones de personas en todo el mundo, con un diagnóstico y tratamiento limitados que dificultan los esfuerzos de eliminación. Ampliar el acceso a diagnósticos y terapias curativas es crucial para lograr los objetivos de la OMS para 2030.

Más Videos Relacionados

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.6K

Videos de Experimentos Relacionados

Last Updated: Jan 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.6K

Área de la Ciencia:

  • Hepatología
  • Enfermedades infecciosas
  • Salud pública

Sus antecedentes:

  • La infección por el virus de la hepatitis C (VHC) es un problema de salud mundial significativo, con aproximadamente 71,1 millones de personas infectadas crónicamente.
  • La transmisión del VHC ocurre principalmente a través de la exposición a la sangre percutánea, con grupos de alto riesgo que incluyen personas que se inyectan drogas, hombres que tienen relaciones sexuales con hombres y prisioneros.
  • La infección crónica por el VHC puede provocar complicaciones graves como cirrosis, insuficiencia hepática y carcinoma hepatocelular en un plazo de 20 a 30 años.

Objetivo del estudio:

  • Para resaltar la carga global de la infección por el virus de la hepatitis C.
  • Para enfatizar la brecha en el diagnóstico y el tratamiento del VHC.
  • Subrayar la importancia de los diagnósticos accesibles y de la terapia antiviral pangenotípica de acción directa para la eliminación del VHC.

Principales métodos:

  • Análisis de los datos epidemiológicos de la incidencia y prevalencia globales del VHC.
  • Revisión de las vías de transmisión y poblaciones de alto riesgo para el VHC.
  • Evaluación de las tasas actuales de diagnóstico y uso del tratamiento para el VHC.

Principales resultados:

  • En 2015, la incidencia mundial del VHC fue de 23,7 por cada 100.000 habitantes, con 1,75 millones de nuevas infecciones.
  • Los genotipos 1, 3 y 4 del VHC son los más prevalentes a nivel mundial.
  • Sólo el 20% de las personas con hepatitis C son conscientes de su diagnóstico, y sólo el 15% de los diagnosticados han recibido tratamiento.

Conclusiones:

  • A pesar de las terapias antivirales curativas de acción directa, persisten importantes obstáculos para el diagnóstico y el tratamiento.
  • Lograr los objetivos de eliminación del VHC de 2030 de la Organización Mundial de la Salud requiere un mayor diagnóstico y vinculación con la atención.
  • El acceso universal a diagnósticos asequibles en el punto de atención y a la terapia antiviral pangenotípica de acción directa es esencial para la erradicación del VHC.